Commentary
Podcast
A brief overview of 4 recent developments in the treatment of non-small cell lung cancer.
This podcast episode provided an oncology news roundup focusing on 4 updates related to non-small cell lung cancer treatment. It discussed the role of pharmacists in chemotherapy management for NSCLC patients and barriers like insurance coverage. It also reviewed two recent FDA drug approvals for advanced NSCLC and results from a phase 3 trial that did not meet its primary endpoint.
[0:00:27-0:01:00] - Pharmacists' involvement among patients with non-small cell lung cancer
[0:01:00-0:02:00] - FDA approval of osimertinib in combination with chemotherapy for EGFR-mutated NSCLC
[0:02:00-0:02:30] - FDA approval of datopotamab deruxtecan for previously treated NSCLC
[0:02:30-0:03:17] - Phase 3 trial of sacituzumab govitecan in metastatic NSCLC that did not meet its primary endpoint
Key Takeaways
FDA Approves Revumenib for the Treatment of Relapsed or Refractory Acute Leukemia
